Lung inflammation as a therapeutic target in cystic fibrosis.
Cystic fibrosis (CF) lung disease is characterized by chronic neutrophilic inflammation and infection. Effective management of airway inflammation could complement other therapies for the treatment of CF. Recent progress has been made in understanding the signaling pathways regulating inflammatory cytokines in the lung. Here we examine the mechanisms responsible for inflammation in the CF lung, and discuss potential therapeutic strategies targeting inflammation.
Koehler
David R
DR
Programme in Lung Biology Research, Hospital for Sick Children, 555 University Ave., Toronto, ON, Canada M5G 1X8.
Downey
Gregory P
GP
Sweezey
Neil B
NB
Tanswell
A Keith
AK
Hu
Jim
J
D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D003550:Cystic Fibrosis / Q000150:complications / Q000503:physiopathology* / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000502:physiology*; D006801:Humans; D018836:Inflammation Mediators / Q000502:physiology*; D008168:Lung / Q000276:immunology / Q000503:physiopathology*
D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; C505032:CFTR protein, human; D018836:Inflammation Mediators; D019005:Cystic Fibrosis Transmembrane Conductance Regulator